(EMBARGO: Chicago, Tuesday, June 3, 2003) Milan based, European School of Oncology (ESO) today announced Catherine Arnst from Business Week, USA as the winner of the ACE Reporter Award 2003 at the 39th annual meeting of the American Society of Clinical Oncology (ASCO). The global initiative launched in 2002 aims to honour accurate and informative cancer journalism.
"Catherine Arnst's entry clearly and accurately informed her readers of advances in oncology treatment, reflecting both the health professional and cancer patient perspectives," said Dr Alberto Costa, ESO's Director. ESO will award Catherine Arnst ?10,000 at an award ceremony scheduled at European Conference of Clinical Oncology (ECCO) 21-25 September 2003 in Copenhagen and will provide an all-expense-paid trip for Ms. Arnst to the congress.
In October 2002, ESO launched a global initiative to honour accurate and informative cancer journalism. The (Awarding Cancer Enlightenment) ACE Reporter Award, was created by ESO to urge journalists across the world to convey a clear interpretation of cancer facts, providing both the medical community and the public with information they can rely upon.
"We were delighted with the quality of entries and the overwhelming number submitted from all over the world," continued Dr. Costa. As a result, ESO is awarding three additional prizes, which comprise invitations to the ESO Oncology Master Class 6-10 March 2004 in Cyprus. Jill Palmer from The Mirror in the United Kingdom, Dominique Pierrat from Top Sante in France and Martina Lenzen-Schulte from Frankfurter Alllgemeine Zeitung in Germany will have the opportunity to work with ESO in developing an educational course for journalists that furthers their knowledge of oncology.
ESO has also awarded a grant of ?1,000 each to: Valeria Roman from Diario Clarin in Argentina, Neika Krasteva from Standard News in Bulgaria, Dinesh Sharma from Hindustan Times in India, Hojun Im from Chosunilbo in Korea and Pavel Walewski from Polityka in Poland. The grants were given to these journalists for providing compelling stories that detail advances in oncology treatments for cancer patients and their families in their respective countries.
ESO also thanks Eli Lilly and Company, a sustaining member of the school's "Learning to Care" programme, for their exclusive partnership on this important initiative to help promote the ACE Reporter Award worldwide. "In sharing ESO's goal of enlightening the journalist community on cancer," said Paolo Paoletti, M.D., vice president of oncology products at Eli Lilly and Company, "we would like to thank all the nominees for their tremendous contribution to the success of the first ACE Reporter Award and encourage participation in the ACE Reporter Award 2004."
Established in 1982, the European School of Oncology is the oldest non-profit organisation exclusively dedicated to increasing health professional's knowledge of cancer care. With a solid foundation, rooted in the best tradition of European medicine and nursing care, the School constantly aims to combine advanced technology with humanism. Therefore, all ESO's educational events are not only clinically orientated, multi-professional and evidence based in nature but also seek to heighten awareness of the cancer patient's experience. The full scientific independence of the School is guaranteed by the receipt of core funding from individual donors and a number of charitable foundations. Since its establishment the language of ESO has been English, however, the School also offers courses and seminars in German, French, Spanish and Italian. In addition, the School organises educational events in Latin America, Russia and the C.I.S., and in the Balkans and Middle East. In addition to its educational activities ESO keeps the European Cancer Community abreast of advances in cancer care via its scientific magazine CancerFutures, published in joint copyright with Springer-Verlag France.
Lilly, a leading innovation-driven corporation is developing a growing portfolio of best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.
Editor's Note: For further information please contact: Louise Pontifex or Paul George at CPR Worldwide on +44 207 282 1200 or Doctor Alberto Costa, Director, European School of Oncology, Viale Beatrice d'Este 37, 20122, Milan, Italy. Tel: +39 02 4335 9611, Fax: +39 02 4335 9640
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania